the want welcome their evening our system. to to Medical’s Thank surgical XXXX first access robotic ability and Titan call. earnings in our and to Enos Good confidence quarter you, Kristen. I support for develop single shareholders thank successfully
story, who share new shareholders investors excited updates today’s with Titan Medical. Titan following with have We’re the to to been and
year Financial that XXXX. going Senior in be Monique Vice will Joining of and into an nicely resulted Officer. Titan positioned Perry and accomplishments of Genova, the call President, today President incredible Development Delorme, Research and Chief Titan Medical on me USA; Medical’s Titan XXXX
milestones million from surgical separated leadership opportunistic followed, accomplish team, offerings. that During with from senior to of system in than the $XX.X exercise the of equity to an held bringing and move continue President grew and Titan and increased XXXX role We and from previous close the and activities million expanded were Labs. Enos investors financings, Board secured $XX.X of patients. the million our equity to Directors, CEO, closer the market weeks Most the financings, noted, recent warrants investor $XX quarter more as communications, first by Living totaling additional launched of Chairman and company and we from received importantly, to activities, the
believes tenure as Board and SemBioSys TSXV sleep of breathing. The He In at Paul have company Director. the we number our brings CEO we the and stage last was governance treatment President a And TSX, governance to best technology demonstrated Board, his a of to appointed Co-Founder corporate specializing as Cataford Trakopolis company joined of trust on as are to with disordered in the during and governance Wireless, Titan the Board Boards and Corporation, IoT sound and we a his As diagnosis of financial Corporate he role listed today Paul Public Board and and companies AgJunction. confidence Sleep Titan’s device served strong company and execute separated experience. of has of critical a practices, principles on of in NASDAQ, Chairman of including Directors significant Director Independent has our each that of as result stakeholders. Lead on medical Zephyr efforts, the of the Sierra Independent And corporate success of and strong earning of corporate leadership Board strategy. and an Technologies, Genetics experience announced transfer Medical’s believe early Directors those Chairman skills are Board. to our Paul been the fall keeping a position the from we that Titan’s CEO. our
We place to of new are him in Board. proud our Chairman the as have
founding Board. brings us to is XX dynamic commercial including delighted for commercial Heather serves Global U.S. experience. years Vice marketing accounts, and Products and France, healthcare of sales, executive is for the Surgical portfolio, Director across national MITG has group, serves she strategy of on Network business where We Chicago Heather General Cheap led where in Heather global Hospital Businesswomen’s growth business currently President leadership. the Technovation Knight Directors proven of sales as sponsor and Heather employee the also the Sofradim, and Medtronic, for today commercialization, a additional Manager Healthcare of as President the of are Heather all announce is resource an nearly all as to as and for Innovations General in at appointed Independent is to Linkage that been She Baxter Committee. of Manager Women’s business, operations served marketing, XXXX integrations. Association previously [ph]. and of Baxter Healthcare, a commercialization initiatives Executive Board Black at She served regions the Co-Chair and and Medtronic the previously including Alliance globe. U.S. Luminary she the women responsible member and executive
to Principal of experience and announce been capital excited the our equally join financial approval Steiner is companies. with where Cathy for currently to Board investment acquisitions Origin at and years brings private capital shareholder are markets finance, companies accounting Partners and responsible Chief banks healthcare management. nominated Officer and has of raising practice. public being in risk Merchant and and annual healthcare in independent through and and of dealings banking upon technology that Previously, over leads Financial mergers the Cathy We she transactions, She the XX meeting. M&A corporate investment Cathy for specializing financial role held oversight
and Director for was decade Managing and commercialization, a she working to transactions, strategic firm, as advisory positioning healthcare Nucleus on well that, financing prior product launch. over clients as For boutique a GC, development, with
World years Cathy is Cipher and Yorkton for of audit Pharmaceuticals, currently Cathy that, to company, member TSX serves healthcare For nearly investment as a Director XX Securities. the banking committee. a prior listed led a and Markets CIBC at
our to until during forward delighted XXXX have and who look professionals and augmented insight success. as talented the Titan’s two the in CFO are previously has these transition serving Board. the retired Stephen Titan’s which join XXXX, their remained during after September have of on Board expertise the Randall, utilizing to period, to September support independence we We Board
systems applying XX and years to Corporate our for visit website team that investor interests. Vice in committee details, compositions. four the respective our Huang will Chien relations contribute for primary Vice responsible our XX distinguished years senior President, We’re We more financial and his as Galfetti investors grateful bios, than the their Kristen expansion executing recently Chien announced CFO leadership strategy member for appointing as implement Stephen’s governance and continued fields is and policy, service develop and to is as Titan’s success. serves the growth Please and Director. years contact and expertise Titan’s media as additional of will for Relations as his has Finance. Kristen Investor support Each Communications, during and the President, over growth. experience and
are We to and have that already meaningful team progress leadership pleased contributing joined they our very are the ways. they in
an Medtronic’s Hill, associated to the a development milestone on access milestone intellectual in support will where program. anticipated adding experienced property under payment to license that to Chapel We also details the in Overall, currently those $XX Perry focused a and Titan Titan team our in experts exciting Titan technology provides more our Titan’s Chapel provide R&D our development North established includes and XX agreement totals portfolio for work staff, to and The R&D completion Hill. million. system now Enos regard technical doing Carolina, license team of both and development month payments. team on for milestones, under achieving and operate those continue the engineers, Medtronic exchange augment portion the leverages over is in from employees. of this Medtronic remains upcoming Medtronic
royalty-free use have to Enos own grow we and in patent platform. that Titan access robotic applications the to to market furthermore, perpetual, as robotic with continue patents worldwide surgery XXX that our single we for there’s believe single demand commercialize for pending. in technologies We high maintains the evolving. system. surgery licensed with Importantly, access rapidly continues innovate our And a portfolio rights global The landscape is over for robotic the versatile
of patient outcomes to improved are throughput. patient the access lower robotic room hospitals efficiency assisted surgeons goals using improved technology looking single remain through functionality. committed patient are operating and enhancing with We cost greater point costs and paramount, outcomes, and greater improved and While for innovative a surgery effectiveness
be easy to reminder, patient medical professionals improve is being a and technology their outcomes. to best Titan’s perform effective allow to to designed As innovative to use both
in Our necessary surgical multi to tasks. common strength confined motion and a for designed remarkable a space articulating of range allow instruments deliver are the
an is movements the during imitates regularly Our that being surgical invasive experience surgical surgery. a and ergonomic system execute real for designed with surgeons provide focus Enos life to that minimally
leading surgeons, feedback and come we Enos opinion to key continue system We with as value to seeing the closely work market. interest in their
developed believe Additionally, market the our believe potential instruments we XD Enos particularly opportunity system to focus to hasten is reduce multi-articulating Titan’s benign for care healing is Enos as increased surgical system’s access has reduce the under-penetrated, is become access visualization, system and an patient’s solution trauma, to and that in XD patient the clinical make that to single being for difference of Enos serve to the scarring. population designed surgeon the for will high-definition surgical system initial workstation ergonomic aiming thus for U.S. lives. and comfort. motivated advantages that vision We robotic a the dexterity market. dual embrace new single surgeon surgery an we is systems standard a improved include The being system The exciting of presenting for include surgery. gynecologic for associated a aim to
success, in versatility found our Enos on the preclinical broad anticipate of multiple that subspecialties. system eventually for based will use Additionally, we be the attractive
opportunities We that and leading needs with have relationships satisfy procedures. unmet hone us feedback continue regarding our to for us excellent with across numerous to provided surgeons insights
pathway and reserved the with the the conversations with first FDA. year As completing we we half novel we process the of anticipate the for applications shared indicate for receipt getting surgical from finalize the via de of previously, We system correspondence and Enos Enos to XXXX, our FDA clinical Investigational expected U.S. progress or Upon of successful product devices. Enos this IDE, file studies the marketing product with upon to second commencing for possible forward of development for in medical expect communications surgeons. our cleared communicating in access the look We and the launch XXXX that to authorization with novo future our the Device is hands Exemption surgical regulatory marketing authorization for of approval system of the FDA half IDE and plan on FDA in into upon XXXX. studies, the system an single
million and meet resulted to Medtronic two of are million of with development in payments. the This we first well-positioned $XX associated we remaining relationship result which in Our the with payment up believe in to license $XX turning XXXX received in in that license program in million. we license Medtronic, $XX XXXX, an remaining the additional payments milestones to two complete milestones an month, in would the expect
Following on payment, the March XX, of our of this an later quarter development Monique providing of will to completed XXXX. finances update received providing this approximately detail million. with phase anticipated $XX is you final as payment be additional end more year license our be
Five, the the And journey enhanced product Labs this in the the with of surgical video our the independence Vice to Enos earlier work another first visit the on with updated to buy our Oppenheimer Corporate over within communications as high provide initiated insertion custom-steerable of David as Martin professionals on and your President encourages of a we Titan Vice stakeholder policy engine, Perry dexterous, launched dedicated and company. development. communication the will on in appreciate of of improve light builds new on multi-articulating April instruments and first X, and who Medical, & increased now definition of XXXX for enhanced over with is shareholder recognizes the the of navigate to work & rating. and we Senior definition is researching contact improved mentioned This rating development second to and with Titan. President an on build Medtronic. independent vignette required ongoing investors. Kristen we available our second to Directors Medical section a Company investor upon the Suraj invite XD you included and copy relating the shareholders analyst earlier, on Titan of website. product that viewers to Burton Genova, our investors one our Company, the of constructive our business. Communications, coverage detailed our XD through XX provides invested video to on website During quarter Enos a Inc., between released navigation activities policy access corporate kinematic engage led of coverage, that hired I pursuant to opportunity initiated on well. corporate activities high displays Titan have our agreement to Four, year established as Dr. we sources, the on activities one website with two The Kalia April camera. last XX, we features lastly, with development the tube, R&D will system. A Relations Bloom in prospects development the this behalf Living XXXX as integrated development as I with update Board work years details camera. license communications view the engagement of coverage Hill, and and team updated We edition toward turn finalizing system section. and And point newest Two, facilitate for communication Thursday, information with buy reporting and improved and other Three, President for and serve a Galfetti Inc., that Chapel USA on regular website of these Titan experience Investor and relations and to audiences our on call investors advancements illustrates
